ScienceMed®

Prognostic value of TAPSE/sPAP in pulmonary arterial hypertension: a systematic review and meta-analysis

Pneumologia
Imagem de arquivo, ilustrativa — não é do estudo. Radiografia de tórax de pulmões saudáveis. N.a. Radiology by Dr. Johan Verbeken. Scan and image editing by Vincent Mia Edie Verheyen · domínio público · Wikimedia Commons

MetanáliseNível 1 · Evidência consolidadaRespiratory medicine7 mai 20261 citações

Salvar

Resumo original em inglês

O que aconteceu

Tricuspid annular plane systolic excursion to systolic pulmonary artery pressure ratio (TAPSE/sPAP) is a simple and validated right ventricle-pulmonary artery (RV-PA) coupling parameter in pulmonary arterial hypertension (PAH). Its prognostic significance for clinical outcomes, however, remains uncertain. This study aimed to evaluate the association between TAPSE/sPAP and key clinical outcomes in PAH.

Medline, Embase, and Cochrane Library were searched from inception to 4 March 2025. Cohort studies evaluating associations between TAPSE/sPAP and clinical outcomes in PAH patients were included. Primary outcome was the composite endpoints of all-cause mortality, lung transplantation after re-evaluation, or clinical worsening. Secondary outcomes included individual components of the primary endpoint, time to clinical worsening (TTCW), and ratio of end-systolic elastance to arterial elastance (Ees/Ea). Hazard ratios (HR) with 95% confidence intervals (CIs) were pooled using a fixed-effect model.

O que encontraram

Fourteen studies were included. Higher baseline TAPSE/sPAP was significantly associated with a lower risk of composite endpoints (dichotomous HR = 0.49; continuous HR = 0.93), reduced all-cause mortality (dichotomous HR = 0.49; continuous HR = 0.94) and lower risk of clinical worsening (dichotomous HR = 0.36; continuous HR = 0.00). Follow-up TAPSE/sPAP was also inversely associated with the composite outcome (dichotomous HR = 0.43). No consistent association was observed between TAPSE/sPAP and Ees/Ea.

Por que isso importa

TAPSE/sPAP is a strong prognostic marker in PAH, significantly associated with lower risk of composite endpoints, all-cause mortality, and clinical worsening. Follow-up TAPSE/sPAP also predicts outcomes, though its evidence for mortality and worsening remains limited and requires further study.

Resumo publicado sob licença CC BY. A tradução para o português ainda não chegou a este estudo.

O estudo original

Prognostic value of TAPSE/sPAP in pulmonary arterial hypertension: a systematic review and meta-analysis

Qin Luo, Sicong Li, Zhihua Huang, Yuqin Ran, Qing Zhao, Li Deng, Zhihui Zhao, Zhihong Liu

Descritores MeSH

  • Pulmonary Arterial Hypertension
  • Pulmonary Artery
  • Tricuspid Valve
  • Echocardiography
  • Humans
  • Prognosis

Veja também

Estudos relacionados